title: [Cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk in Spain].
abstract: OBJECTIVE
  To estimate the cost-effectiveness of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in Spain, according to the European guidelines for the treatment of dyslipidemias in patients with high and very high cardiovascular risk.
  
  
  METHODS
  A Markov long-term cost-effectiveness model of rosuvastatin versus simvastatin, atorvastatin and pitavastatin in patients with high and very high cardiovascular risk defined according to 5 factors (sex, age, smoking habit, baseline cholesterol level, and systolic blood pressure) using the SCORE system. The incremental cost-effectiveness ratio is expressed in euros per quality adjusted life years and is calculated according to the perspective of the Spanish National Health System.
  
  
  RESULTS
  Rosuvastatin is associated with a greater health benefit than the other statins across the considered profiles. Rosuvastatin is cost-effective compared to simvastatin in patients with SCORE risk ≥8% in females and ≥6% in males, while between 5% and the indicated values its cost-effectiveness is conditional to the patient baseline c-LDL level. Rosuvastatin is more cost-effective versus atorvastatin in female profiles associated with a SCORE risk≥11% and male profiles with SCORE risk ≥10%. Rosuvastatin is superior versus pitavastatin in both female and male profiles with high and very high cardiovascular risk.
  
  
  CONCLUSIONS
  Rosuvastatin is a cost-effective therapy in the treatment of hypercholesterolemia versus simvastatin, atorvastatin and pitavastatin, especially in specific profiles of patients with high and very high cardiovascular risk factors, according to the SCORE system, in Spain.
authors: Servicio de Cardiología, Hospital Arnau de Vilanova, Valencia, España.
authors: Juan
authors: J
authors: Cosin Sales
authors: Unidad de Lípidos y Aterosclerosis, Departamento de Medicina, IMIBIC/Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba y CIBER Fisiopatología Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, España.
authors: Francisco José
authors: FJ
authors: Fuentes Jiménez
authors: Centro de Salud Universitario Prosperidad, Madrid, España.
authors: Teresa
authors: T
authors: Mantilla Morató
authors: Departamento Científico, Ferrer Internacional, Barcelona, España.
authors: Emilio
authors: E
authors: Ruiz
authors: Departamento Científico, Ferrer Internacional, Barcelona, España.
authors: Virginia
authors: V
authors: Becerra
authors: Outcomes'10, Castellón de la Plana, España.
authors: Susana
authors: S
authors: Aceituno
authors: Outcomes'10, Castellón de la Plana, España.
authors: Maria Giovanna
authors: MG
authors: Ferrario
authors: Outcomes'10, Castellón de la Plana, España.
authors: Luis
authors: L
authors: Lizán
authors: Departamento Científico, Ferrer Internacional, Barcelona, España. Electronic address: alfredogracia@ferrer.com.
authors: Alfredo
authors: A
authors: Gracia
mesh_terms: D000328:Adult; D000368:Aged; D000069059:Atorvastatin / Q000191:economics / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000191:economics / Q000209:etiology / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy* / Q000191:economics; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics / Q000627:therapeutic use*; D008297:Male; D008390:Markov Chains; D008875:Middle Aged; D018803:Models, Economic; D011804:Quinolines / Q000191:economics / Q000627:therapeutic use; D012307:Risk Factors; D000068718:Rosuvastatin Calcium / Q000191:economics / Q000627:therapeutic use*; D019821:Simvastatin / Q000191:economics / Q000627:therapeutic use; D013030:Spain
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011804:Quinolines; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin; D019821:Simvastatin; C108475:pitavastatin
keywords: Análisis coste-beneficio; Cardiovascular risk; Cost-benefit analysis; Estatinas; Riesgo cardiovascular; Rosuvastatin; Rosuvastatina; Statins; Systematic Coronary Risk Estimation